These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 22920685)

  • 1. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.
    Smits ML; Nijsen JF; van den Bosch MA; Lam MG; Vente MA; Mali WP; van Het Schip AD; Zonnenberg BA
    Lancet Oncol; 2012 Oct; 13(10):1025-34. PubMed ID: 22920685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study.
    Braat AJAT; Prince JF; van Rooij R; Bruijnen RCG; van den Bosch MAAJ; Lam MGEH
    Eur Radiol; 2018 Mar; 28(3):920-928. PubMed ID: 28786008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
    Braat AJAT; Bruijnen RCG; van Rooij R; Braat MNGJA; Wessels FJ; van Leeuwaarde RS; van Treijen MJC; de Herder WW; Hofland J; Tesselaar MET; de Jong HWAM; Lam MGEH
    Lancet Oncol; 2020 Apr; 21(4):561-570. PubMed ID: 32112737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.
    Elschot M; Nijsen JF; Lam MG; Smits ML; Prince JF; Viergever MA; van den Bosch MA; Zonnenberg BA; de Jong HW
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1965-75. PubMed ID: 24819055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial.
    Smits ML; Nijsen JF; van den Bosch MA; Lam MG; Vente MA; Huijbregts JE; van het Schip AD; Elschot M; Bult W; de Jong HW; Meulenhoff PC; Zonnenberg BA
    J Exp Clin Cancer Res; 2010 Jun; 29(1):70. PubMed ID: 20550679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres.
    Prince JF; van Rooij R; Bol GH; de Jong HW; van den Bosch MA; Lam MG
    J Nucl Med; 2015 Jun; 56(6):817-23. PubMed ID: 25931477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Radioembolization with
    Prince JF; van den Bosch MAAJ; Nijsen JFW; Smits MLJ; van den Hoven AF; Nikolakopoulos S; Wessels FJ; Bruijnen RCG; Braat MNGJA; Zonnenberg BA; Lam MGEH
    J Nucl Med; 2018 Apr; 59(4):582-588. PubMed ID: 28916623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo dosimetry based on SPECT and MR imaging of 166Ho-microspheres for treatment of liver malignancies.
    Smits ML; Elschot M; van den Bosch MA; van de Maat GH; van het Schip AD; Zonnenberg BA; Seevinck PR; Verkooijen HM; Bakker CJ; de Jong HW; Lam MG; Nijsen JF
    J Nucl Med; 2013 Dec; 54(12):2093-100. PubMed ID: 24136931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The superior predictive value of
    Smits MLJ; Dassen MG; Prince JF; Braat AJAT; Beijst C; Bruijnen RCG; de Jong HWAM; Lam MGEH
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):798-806. PubMed ID: 31399801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation.
    van de Maat GH; Seevinck PR; Elschot M; Smits ML; de Leeuw H; van Het Schip AD; Vente MA; Zonnenberg BA; de Jong HW; Lam MG; Viergever MA; van den Bosch MA; Nijsen JF; Bakker CJ
    Eur Radiol; 2013 Mar; 23(3):827-35. PubMed ID: 23014797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [
    Wagemans MEHM; Braat AJAT; van Rooij R; Smits MLJ; Bruijnen RCG; Prince JF; Bol GM; de Jong HWAM; Lam MGEH
    Cardiovasc Intervent Radiol; 2024 Apr; 47(4):443-450. PubMed ID: 38326577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of body surface area-based activity calculation for radioembolization of hepatic metastases in colorectal cancer.
    Lam MG; Louie JD; Abdelmaksoud MH; Fisher GA; Cho-Phan CD; Sze DY
    J Vasc Interv Radiol; 2014 Jul; 25(7):1085-93. PubMed ID: 24457263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT.
    Chansanti O; Jahangiri Y; Matsui Y; Adachi A; Geeratikun Y; Kaufman JA; Kolbeck KJ; Stevens JS; Farsad K
    J Vasc Interv Radiol; 2017 Nov; 28(11):1528-1535. PubMed ID: 28888827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-Effect Relationships of
    van Roekel C; Bastiaannet R; Smits MLJ; Bruijnen RC; Braat AJAT; de Jong HWAM; Elias SG; Lam MGEH
    J Nucl Med; 2021 Feb; 62(2):272-279. PubMed ID: 32591491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
    Lewandowski RJ; Thurston KG; Goin JE; Wong CY; Gates VL; Van Buskirk M; Geschwind JF; Salem R
    J Vasc Interv Radiol; 2005 Dec; 16(12):1641-51. PubMed ID: 16371530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioembolisation with Yttrium-90 microspheres: an effective treatment modality for unresectable liver metastases.
    Bester L; Meteling B; Pocock N; Saxena A; Chua TC; Morris DL
    J Med Imaging Radiat Oncol; 2013 Feb; 57(1):72-80. PubMed ID: 23374558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization.
    Liepe K; Brogsitter C; Leonhard J; Wunderlich G; Hliscs R; Pinkert J; Folprecht G; Kotzerke J
    Jpn J Clin Oncol; 2007 Dec; 37(12):942-50. PubMed ID: 18094017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-effect relationships in neuroendocrine tumour liver metastases treated with [
    Ramdhani K; Beijer-Verduin J; Ebbers SC; van Rooij R; Smits MLJ; Bruijnen RCG; de Jong HWAM; Lam MGEH; Braat AJAT
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2114-2123. PubMed ID: 38369678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.